1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Grape King Bio Ltd.

Grape King Bio Ltd.

TTWSE:1707
85.20
TWD
-0.40
(-0.47%)
11.88EPS
11.88P/E
13.64BMarket Cap
Nov 11Next Earn
Grape King Bio Ltd.
TWSE:1707
(Taiwan Stock Exchange)

Recent

price

85.20

P/E

ratio

11.88

div

yld

7.52%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
25.2
28.96
35.41
43.3
48.24
55.65
69.59
69.67
67.84
68
67.35
66.4
70.15
71.79
75.34
69.2
68.36
Revenue per Share
3.28
3.63
4.67
6.42
7.24
8.07
9.82
10.03
9.57
9.63
9.34
8.81
9.84
9.81
9.78
8.22
7.75
Basic EPS, GAAP
-0.37
5.41
7.75
9.38
9.66
-10.21
15.53
12.77
9.57
11.16
10.97
15.34
16.8
12.95
8.29
11.59
9.98
Free Cash Flow per Basic Share
2.69
3.44
4.28
5.27
6.9
8.37
8.23
9.55
6.67
6.5
6.5
6.43
6.1
6.9
6.9
6.9
6.4
Dividend per Share
15.94
16.85
18.53
21.28
23.58
26.69
35.56
38.57
42.2
45.38
48.61
60.68
64.6
67.36
67.88
69.81
69.11
Book Value per Share
15.49
16.85
18.53
21.28
23.49
26.59
35.36
38.4
42.06
45.13
48.33
60.45
64.31
66.51
67.08
69.08
68.4
Tangible Book Value per Share
130
130
130
130
130
130
132
135
135
136
136
148
148
148
148
148
148
Basic Weighted Avg Shares
3,282
3,771
4,612
5,639
6,283
7,248
9,185
9,388
9,183
9,239
9,168
9,798
10,391
10,635
11,160
10,252
10,122
Sales/Revenue/Turnover
19.93
20.43
21
23.58
25.46
25.01
24.32
24.01
25.59
25.27
25.14
23.6
24.57
23.5
22.4
20.88
20.11
Operating Margin (%)
86
100
114
123
129
150
209
225
261
319
415
427
450
460
513
557
563
Depreciation Expense
428
473
608
836
942
1,052
1,297
1,352
1,295
1,309
1,272
1,300
1,457
1,453
1,448
1,218
1,148
Net Income, GAAP
18.69
19.24
17.69
17.23
17.92
17.83
18.4
19.57
22.11
20.55
20.31
19.33
19.28
19.51
18.78
19.01
19.08
Effective Tax Rate (%)
13.03
12.54
13.19
14.82
15
14.51
14.12
14.4
14.11
14.17
13.87
13.27
14.02
13.66
12.98
11.88
11.34
Profit Margin (%)
432
657
884
612
503
862
497
11
-377
256
471
1,691
2,089
2,391
2,273
2,240
1,864
Working Capital
- -
- -
- -
- -
- -
2,413
1,113
519
293
941
1,493
216
111
136
107
143
120
LT Debt
2,260
2,442
2,721
3,221
3,717
4,220
5,783
6,328
6,933
7,471
7,978
10,429
11,141
11,630
11,791
12,066
11,604
Total Equity
22.17
24.94
29.27
35.22
35.69
27.38
25.65
24.27
22.9
21.26
18.48
16.64
17.2
15.95
16.12
13.72
13.73
Return on Invested Capital (%)
12.79
11.94
14.57
16.42
14.23
10.96
10.67
10.91
9.24
8.22
7
6.32
6.79
6.63
6.12
4.78
4.56
Return on Capital (%)
21.31
22.16
26.41
32.24
32.26
32.12
31.3
27.03
23.71
21.99
19.88
16.66
15.7
14.86
14.46
11.95
11.45
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
72
72
67
LT Borrowings
- -
- -
- -
LT Finance Leases
143
129
120
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
148
148
148
Market Capitalization
18,739
17,925
13,643

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,661
5,420
5,034
Cash, Cash Equivalents & STI
4,278
4,091
3,703
Accounts Receivable, Net
337
420
336
Inventories
829
755
812
Total Current Liabilities
3,421
3,397
3,170
Payables & Accruals
- -
- -
- -
ST Debt
72
72
67
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.62%
9.13%
2.34%
Free Cash Flow
-23.69%
8.48%
39.75%
Net Income, GAAP
1.94%
-0.44%
-15.88%
Sales/Revenue/Turnover
3.87%
2.41%
-8.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,348
2,758
2,899
3,155
11,160
2025
2,252
2,569
2,428
3,002
10,252
2026
2,278
2,414
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.74
2.21
2.81
3.02
9.78
2025
1.4
1.82
2
3
8.22
2026
1.18
1.57
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6.9
2025
2.7
- -
4.2
- -
6.9
2026
2.2
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Grape King Bio Ltd operates as a biotechnology company specializing in the development, manufacture, and sale of health food products, pharmaceutical preparations, and functional beverages. Its main product portfolio includes Chinese herbal medicines, probiotic supplements, energy drinks, and health food supplements targeting gastrointestinal health, immunity regulation, female beauty, and general health care. The company provides OEM/ODM services with advanced manufacturing capabilities such as capsules, sachets, glass bottles, aseptic filling packaging, and retort pouch production lines. Its products are marketed primarily in Taiwan, China, Southeast Asia, and other international markets. Founded in 1969 and headquartered in Taiwan, Grape King Bio leverages a robust R&D team that focuses on mushroom mycelium-based ingredients (including Ganoderma lucidum, Antrodia cinnamomea, Hericium erinaceus) and functional probiotics, supported by numerous patents, clinical studies, and international quality certifications. In recent years, Grape King Bio has strategically expanded its operations by entering partnerships and joint ventures, including a significant collaboration with Uni-President Enterprises Corporation, which acquired an 8% stake in Grape King in 2020. This alliance has enabled greater penetration into the fast-moving consumer goods (FMCG) market and retail channels. Additionally, Grape King Bio has advanced its global pharmaceutical business by beginning probiotic product shipments to a leading global pharmaceutical company and expanding sales channels into Southeast Asia, with Malaysia as a key growth market. The company has further demonstrated commitment to sustainable development by joining RE100, adopting net zero emission targets validated by the Science-based Targets Initiative, and implementing international environmental and anti-bribery management standards. It operates multiple production and research facilities in Taiwan including its headquarters, manufacturing sites, and biotech research institutes. Grape King Bio’s recent product innovations include new health supplements and functional beverages co-developed with partners like Uni-President, aiming at enhancing consumer health benefits and expanding market reach. The company maintains a leadership position in biotechnology-driven health food production with capabilities in fermentation technology and high-standard quality control to meet international food safety and pharmaceutical-grade standards. This comprehensive approach positions Grape King Bio Ltd as a leading biotechnology company focused on health food and pharmaceutical products, leveraging scientific innovation, strategic alliances, and sustainability to drive growth in regional and global markets.